Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2839 The Second Revision of Clinical Practice Guidelines in GEP-NEN in Japan
Introduction: Japanese Neuroendocrine Tumor Society (JNETS) has published the first edition of clinical practice guidelines in gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) in 2015. Then, according to an update on the diagnosis and management of GEP-NEN in Japan. Revised clinical practice guidelines, the second edition, has just published in 2019.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,
Keywords: Streptozocin, pNETs,
Introduction: Neuroendocrine carcinomas (NEC) (high grade Ki67 > 20%) were poor prognostic and lethal disease. Platinum-based chemotherapy is usually chosen as a first line treatment for advanced NEC, however, this efficacy is temporary and there is no standard second-line treatment yet. Temozolomide is a good candidate, however it was not approved for NEC by Japanese authorities.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Ichikawa Y, Kobayashi N, Tokuhisa M, Goto A, Hiroshima Y,
Keywords: Neuroendocrine Carcinoma, Temozolomide,
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Kasajima A
Authors: Kasajima A, Tachibana T, Ishida H, Yazdani S, Konukiewitz B,
Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Miki M, Ito T, Hijioka M, Kawabe K, Jensen R,
Keywords: Pancreatic neuroendocrine tumors, Chromogranin A, Chromogranin B,